Novartis agreed to pay $347 million to resolve FCPA offences for improper conduct in 2020
The Foreign Corrupt Practices Act (FCPA), enacted in 1977, disallows the payment of bribes to foreign officials for expanding or obtaining businesses1. The violations of the anti-bribery provisions of the FCPA can include criminal penalties of up to $2,000,000 for the corporations2.
Novartis spent over $100 million in kickbacks to doctors to influence them to prescribe their drugs
Kickbacks are frequently used by pharmaceutical companies to persuade physicians, pharmacies, healthcare providers and nurses to favour the company’s medication or treatment over a competitor’s to increase their profits1. In the U.S.A, "Between 2013 and 2016, doctors received payments from pharmaceutical companies for a total of $9 billion. Those who received industry payments were two to three times more likely to prescribe name-brand drugs than their peers2, 8.
Novartis' Familia Nawiri (Healthy Family Initiative) helps to improve healthcare service provision in Kenya
Good health is essential to sustainable development and the 2030 Agenda reflects the complexity and interconnectedness of the two1. According to UNDP, at least 400 million people have no basic healthcare, and 40 percent lack social protection. Every 2 seconds someone aged 30 to 70 years dies prematurely from noncommunicable diseases - cardiovascular disease, chronic respiratory disease, diabetes or cancer1 . It is for these reasons that Novartis plays an important role in healthcare provision in the developing world. For example, in 2009, 387,000 patients in Peru, Bolivia and Yemen benefited from a program that involved collaboration between Novartis and WHO in which the former provided drugs for treating Fascioliasis2.
Novartis provided health education to 10 million people in 2019 through Novartis Social Business program
According to the WHO, over four million people lack access to quality health care and medical education globally1. This is mainly because of the uneven availability of health workers and accessibility to medical educational programs around the world1.
Novartis reduces 80,000 tons of Scope 1 & 2 CO2 emissions in 2019
In 2018, 6,667 million metric tons of CO2 (81% in GHGs) emissions were recorded 1. 48.6 tonnes of CO2 equivalent per million dollars emission came from the pharmaceutical industry in 2015 globally 2 which was 55% more than the automotive sector for the same year 2.